Article Sidebar

PDF
Date Published: 24/07/2021
Abstract Views: 145
Views PDF: 214
DOI: https://doi.org/10.51298/vmj.v502i1.545
Issue
Vol. 502 No. 1 (2021)
Section
Các bài báo
How to Cite
Thanh Huyền, M. ., & Thị Thái Hoà, N. (2021). PROGNOSIS FACTORS OF ADVANCED STAGE NON-SMALL LUNG CANCER AFTER EGFR TKIs ACCQUIRED RESISTANCE. Vietnam Medical Journal, 502(1). https://doi.org/10.51298/vmj.v502i1.545

PROGNOSIS FACTORS OF ADVANCED STAGE NON-SMALL LUNG CANCER AFTER EGFR TKIs ACCQUIRED RESISTANCE

Mai Thanh Huyền, Nguyễn Thị Thái Hoà

Main Article Content

Abstract

Objective: To evaluate prognosis factors of advanced non-small cell lung cancer after accquired resistance to EGFR TKIs treated with Pemetrexed - Carboplatin regimen. Objects and methods: 46 patients with advanced non-small cell lung cancer with EGFR mutation, secondary resistance to TKIs, no or unknown T790M mutation, treatment withPemetrexed - Carboplatin. Retrospective studies with vertical follow-up. Results: PS0 has mPFS for 5 months, PS1 has mPFS for 3.5 months. mPFS in patients with brain metastasis: 3.3 months; no brain metastases: 5.6 months. mPFS for phase IIIB is 7 months, phase IV is 3 months. A TKI response over 6 months with an mPFS of 7 months, a response less than 6 months with an mPFS of 2.5 months. Conclusion: Brain metastasis, stage IV, response time to first line treatment TKI less than 6 months are prognostic factors with short progression - free survival with Pemetrexed – Carboplatin treated.

Article Details

Keywords

Lung cancer, non-small cell, secondary resistance to EGFR TKIs, chemotherapy, progression - free survival

References

1. Scagliotti G., Park K., Patil S., Rolski J., Goksel T., Martins R., et al (2009). Survival without toxicity for cisplatin plus Pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer, 45, 2298–2303.
2. Scagliotti G.V. (2005). Pemetrexed plus carboplatin or oxaliplatin in advanced non small cell lung cancer. Semin Oncol, 32(2 Suppl 2), S5-8
3. Metro G., Chiari R., Mare M.et al. (2011). Carboplatin plus pemetrexed for platinum pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol, 68(6), 1405–1412.
4. Ito M, Horita N, Nagashima A, Kaneko T(2019). Carboplatin pluspemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Asia Pac J Clin Oncol. 2019 Apr;15(2):e3-e10. doi: 10.1111/ajco.12837. Epub 2018 Jan 8.PMID: 29316288
5. Trương Văn Sáng (2019). Đánh giá kết quả điều trị phác đồ Pemetrexed – Carboplatin trên bệnh nhân ung thư biểu mô tuyến của phổi giai đoạn IV. Luận vănThạc sĩ Chuyên ngành Ung thư.
6. Tony S. Mok, Yi-Long Wu, Myung-Ju Ahn, et al (2017). Osimertinib or PlatinumPemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med 2017; 376:629-640DOI: 10.1056/ NEJMoa1612674